ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Juvenile idiopathic arthritis"

  • Abstract Number: 0722 • ACR Convergence 2020

    Evaluation of Flare Rate and Tapering Strategies in Juvenile Idiopathic Arthritis

    Antía García-Fernández1, Andrea Briones-Figueroa1, Laura Calvo-Sanz1, África Andreu Suárez1 and Alina Lucica Boteanu2, 1Rheumatology, Hospital Universitario Ramón y Cajal, Madrid, Spain, 2PRINTO, Istituto Giannina Gaslini, Genova, Italy

    Background/Purpose: Biological treatment (BT) has changed the perspectives of Juvenile Idiopathic Arthritis (JIA) patients, but it remains unclear when and how to taper or to withdraw…
  • Abstract Number: 1154 • ACR Convergence 2020

    Distinct Gene Signature Predicts Strong Clinical Responses to Canakinumab in Children with Systemic Juvenile Idiopathic Arthritis

    Emely Verweyen1, Alex Pickering2, Alexei Grom3 and Grant Schulert4, 1Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2Harvard Medical School, Boston, MA, 3Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 4PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH

    Background/Purpose: Canakinumab is a human anti-IL1β blocking agent that effectively neutralizes IL1β mediated signaling and is used to treat diseases such as systemic juvenile idiopathic…
  • Abstract Number: 0172 • ACR Convergence 2020

    Early Treatment and IL1RN Single Nucleotide Polymorphisms Affect Response to Anakinra in Systemic Juvenile Idiopathic Arthritis

    Marianna Nicoletta Rossi1, Manuela Pardeo2, Denise Pires Marafon2, Emanuela Sacco2, Chiara Passarelli3, Claudia Bracaglia2, Chiara Perrone3, Anna Tulone4, Giusi Prencipe5 and Fabrizio De Benedetti6, 1Laboratory of Immuno-Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Lazio, Italy, 2Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, Rome, Italy, 3U.O.C. Laboratory of Medical Genetics, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, 4Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, 5Laboratory of Immuno-Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesu', Rome, Italy, 6Division of Rheumatology, Laboratory of Immuno-Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, Rome, Italy

    Background/Purpose: Systemic juvenile idiopathic arthritis (sJIA) represents 10-20% of all chronic arthritis during childhood. The interleukin 1 (IL-1) play a pivotal role in the pathogenesis…
  • Abstract Number: 0723 • ACR Convergence 2020

    Social Determinants of Health and Time to First Pediatric Rheumatology Appointment in Polyarticular Juvenile Idiopathic Arthritis

    Nayimisha Balmuri1, Victoria Cooley2, Linda Gerber2, Susan Goodman3, Bella Mehta3 and Karen Onel4, 1Hospital for Special Surgery, new york, NY, 2Weill Cornell Medicine, NY, NY, 3Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, 4Pediatric Rheumatology, Hospital for Special Surgery, New York, NY

    Background/Purpose: Patients with polyarticular JIA (pJIA) have a refractory disease course with increased risk for joint damage resulting in poor functional outcome and decreased quality of…
  • Abstract Number: 1155 • ACR Convergence 2020

    Long-term Safety Profile of Anakinra in Patients with Systemic Juvenile Idiopathic Arthritis

    Gabriella Giancane1, Riccardo Papa1, Sebastiaan Vastert2, Francesca Bagnasco1, Joost Swart1, Pierre Quartier3, Jordi Anton4, Isabelle Kone Paut1, Sylvia Kamphuis1, Troels Herlin5, Helga Sanner1, Fabrizio De Benedetti6, Elena Tsitsami7, Susan Mary Nielsen1, Estefania Moreno1, Chiara Pallotti1, Karin Franck-Larsson8, Håkan Malmström8, Susanna Cederholm9, Nico Wulffraat1 and Nicolino Ruperto10, 1IRCCS Istituto Giannina Gaslini, PRINTO, Genoa, Italy, Genova, Italy, 2University Medical Center Utrecht, Utrecht, Netherlands, 3Necker-Enfants Malades University Hospital, Assistance Publique-Hopitaux de Paris, Paris, France, 4Sant Joan de Déu Hospital, Madrid, Spain, 5Aarhus University Hospital, Aarhus, Denmark, 6Division of Rheumatology, Laboratory of Immuno-Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, Rome, Italy, 7Aghia Sophia Childrens Hospital, Athens, Greece, 8Swedish Orphan Biovitrum, Stockholm, Sweden, 9Sobi, Stockholm, Sweden, 10PRINTO, Istituto Giannina Gaslini, Genova, Italy

    Background/Purpose: To evaluate the long-term safety profile of anakinra in patients with systemic juvenile idiopathic arthritis (sJIA)Methods: Data from patients with sJIA according to the…
  • Abstract Number: 0173 • ACR Convergence 2020

    mTORC1 Signaling Promotes Monocytosis and Arthritis Development in IL-1 Receptor Antagonist-deficient Mice

    Zhengping Huang1, Ying Li2, Alexandra Wactor3, Peter Nigrovic4 and Pui Lee5, 11.Guangdong Second Provincial General Hospital;2.Brigham and Women's Hospital;3.Harvard Medical School, BOSTON, MA, 21.Brandeis University;2.Brigham and Women's Hospital, Waltham, MA, 3Brigham and Women's Hospital, Boston, MA, 4Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA, Boston, 51.Boston Children's Hospital;2.Brigham and Women's Hospital;3.Harvard Medical School, Newton, MA

    Background/Purpose: Systemic juvenile idiopathic arthritis (sJIA) is potentially life-threatening disease characterized by prolonged fever, systemic inflammation and skin rash in addition to joint inflammation. Aberrant…
  • Abstract Number: 0724 • ACR Convergence 2020

    Anxiety and Depressive Symptoms in Juvenile Idiopathic Arthritis (JIA) Correlate with Pain and Stress Using Patient-Reported Outcomes Measurement Information System (PROMIS®)

    Danielle Fair1, Judyann Olson2, Jan Lemke1, Stella Protopapas3, Ke Yan2 and Jian Zhang2, 1Children's Wisconsin, Milwaukee, WI, 2Medical College of Wisconsin, Milwaukee, WI, 3Riley Children's Hospital at Indiana University, Indianapolis, IN

    Background/Purpose: Children with chronic diseases have higher rates of mental health issues and less favorable outcomes than the general pediatric population.  Children with JIA experience…
  • Abstract Number: 1492 • ACR Convergence 2020

    The Childhood Arthritis and Rheumatology Research Alliance Start Time Optimization of Biologic Therapy in Polyarticular JIA Study: Report of Primary Study Outcomes

    Yukiko Kimura1, George Tomlinson2, Laura Schanberg3, Mary Ellen Riordan4, Anne Dennos5, Vincent Del Gaizo6, Katherine Murphy7, Pamela F. Weiss8, Brian Feldman9 and Sarah Ringold10, 1Hackensack Meridian School of Medicine, Hackensack, NJ, 2Department of Medicine, University Hospital Network, Toronto, Toronto, ON, Canada, 3Duke University Medical Center, Durham, NC, 4Hackensack University Medical Center, Westwood, NJ, 5Duke University, Durham, NC, 6Childhood Arthritis & Rheumatology Research Alliance (CARRA), Whitehouse Station, NJ, 7Lousiana Department of Public Health, New Orleans, LA, 8Children's Hospital of Philadelphia, Philadelphia, 9The Hospital for Sick Children, Toronto, ON, Canada, 10Seattle Children's, Seattle, WA

    Background/Purpose: There is uncertainty regarding when to start biologic medications for polyarticular juvenile idiopathic arthritis (P-JIA). The Childhood Arthritis and Rheumatology Research Alliance (CARRA) developed…
  • Abstract Number: 0174 • ACR Convergence 2020

    Dense Genotyping of Immunologic Loci Identifies CXCR4 as a Novel Susceptibility Locus for Systemic Juvenile Idiopathic Arthritis

    Emily Shuldiner1, Elaine Remmers2, Miranda Marion3, Marc Sudman4, Colleen Satorius5, Patricia Woo6, Sampath Prahalad7, Carl Langefeld8, Susan Thompson9, Wendy Thomson10 and Michael Ombrello11, 1NIAMS, NIH, Bethesda, 2National Human Genome Research Institute (NHGRI), NIH, Bethesda, MD, 3Wake Forest School of Medicine, Winston-Salem, 4Cincinnati Children's Hospital Medical Center, Cincinnati, 5NHGRI, NIH, Bethesda, 6Great Ormond Street Hospital, London, United Kingdom, 7Emory + Children's Pediatric Institute, Atlanta, GA, 8Wake Forest School of Medicine, Winston Salem, NC, 9Cincinnati Children's Hospital Medical Center/Univ of Cincinnati College of Medicine, Cincinnati, OH, 10Centre for Genetics and Genomics Versus Arthritis, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom, 11Translational Genetics and Genomics Unit, NIAMS, NIH, Bethesda, MD

    Background/Purpose: Systemic juvenile idiopathic arthritis (sJIA) is a severe, potentially lethal inflammatory condition. It accounts for a disproportionate share of morbidity and mortality among childhood…
  • Abstract Number: 0725 • ACR Convergence 2020

    A Data Science Evaluation of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) Questionnaire for Improving Management of JIA Patients

    Humbert Quesada-Masachs1, Michalis Faloutsos2, Shomit Ghose3, Sara Marsal4, Consuelo Modesto4 and Estefania Quesada-Masachs5, 1University of California Riverside, San Diego, 2University of California Riverside, Riverside, 3University of California Berkeley, San Francisco, 4Hospital Universitari Vall d'Hebron, Barcelona, Spain, 5Hospital Universitari Vall d'Hebron, San Diego

    Background/Purpose: The Juvenile Arthritis Multidimensional Assessment Report (JAMAR) is a questionnaire developed to comprehensively assess Juvenile Idiopathic Arthritis (JIA) patients. Despite being translated into 54…
  • Abstract Number: 1493 • ACR Convergence 2020

    Distinct Patient-level Patterns of Response to Methotrexate in Juvenile Idiopathic Arthritis

    Stephanie Shoop-Worrall1, Kimme Hyrich2, Lucy Wedderburn3, Wendy Thomson4 and Nophar Geifman5, 1Centre for Health Informatics, Centre for Epidemiology Versus Arthritis, The University of Manchester, Manchester, United Kingdom, 2Centre for Epidemiology Versus Arthritis, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom, 3UCL, UCLH, GOS Institute of Child Health, London, United Kingdom, 4Centre for Genetics and Genomics Versus Arthritis, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom, 5Centre for Health Informatics, The University of Manchester, Manchester

    Background/Purpose: Treatment response in JIA is often viewed as a binary outcome: response or non-response, usually assessed using composite, multidimensional measures, such as the juvenile…
  • Abstract Number: 0469 • ACR Convergence 2020

    IFNγ Is Essential for Alveolar Macrophage Driven Lung Inflammation in Macrophage Activation Syndrome

    Denny Gao1, Maggie Henderlight1, Christopher Woods1, Alexei Grom1, Sherry Thornton1, Michael Jordan1, Katheryn Wikenheiser-Brokamp1 and Grant Schulert2, 1Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH

    Background/Purpose: Macrophage activation syndrome (MAS) is a life-threatening cytokine storm syndrome frequently complicating systemic juvenile idiopathic arthritis (SJIA) and driven by IFNγ. MAS is also…
  • Abstract Number: 0727 • ACR Convergence 2020

    Hip Involvement Leads to Poor Outcome in Adulthood in Children with Enthesitis Related Arthritis (ERA) Category of Juvenile Idiopathic Arthritis (JIA)

    Naveen R1, Namita Mohindra1, Neeraj Jain1 and Amita Aggarwal2, 1Sanjay Gandhi Post graduate institute of medical sciences, Lucknow, Uttar Pradesh, India, 2Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India

    Background/Purpose: Enthesitis related arthritis (ERA) is the commonest category of JIA seen in India and constitutes 30-40% of all JIA patients. There are many studies…
  • Abstract Number: 1494 • ACR Convergence 2020

    Patient-Reported Adverse Events, Quality of Life and Treatment Adherence in Juvenile Idiopathic Arthritis: Analysis of Two Large International Cohorts

    Alessandra Alongi1, Maria Trachana2, Valda Stanevicha3, Laura Marinela Ailioaie4, Elena Tsitsami5, Angelo Ravelli6, Alessandro Consolaro6 and Nicolino Ruperto7, 1IRCCS Istituto Giannina Gaslini, Genoa, Italy, 2Aristotle University of Thessaloniki, Thessaloníki, Greece, 3Riga Stradins University, Riga, Latvia, 4Alexandru Ioan Cuza University of Iasi, Iasi, Romania, 5Aghia Sophia Childrens Hospital, Athens, Greece, 6Università degli Studi di Genova, Genoa, Italy, 7Istituto Giannina Gaslini, Genova, Italy

    Background/Purpose: Juvenile idiopathic arthritis (JIA) patients may experience significant medication-related adverse effects (AEs), which may adversely affect health-related quality of life (HRQOL), daily activities and…
  • Abstract Number: 0470 • ACR Convergence 2020

    Th1 Polarization Defines the T Cell Compartment in the Joints of Oligoarticular Juvenile Idiopathic Arthritis Patients

    Amelie Jule1, Kacie Hoyt1, Kevin Wei2, Siobhan Case3, Margaret Chang1, Ezra Cohen1, Fatma Dedeoglu1, Melissa Hazen1, Jonathan Hausmann4, Olha Halyabar5, Erin Janssen5, Pui Lee6, Jeffrey Lo1, Mindy Lo1, Esra Meidan7, Jordan Roberts1, Mary Beth Son1, Robert Sundel5, Talal Chatila1, Peter Nigrovic8 and Lauren Henderson9, 1Boston Children's Hospital, Boston, MA, 2Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 3Brigham and Women's Hospital, Boston, MA, 4Boston Children's Hospital / Beth Israel Deaconess Medical Center, Cambridge, MA, 5Children's Hospital/Boston Medical Center, Boston, MA, 61.Boston Children's Hospital;2.Brigham and Women's Hospital;3.Harvard Medical School, Newton, MA, 7Boston Children's Hospital, Somerville, MA, 8Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA, Boston, 9Boston Children's Hospital, Watertown, MA

    Background/Purpose: Oligoarticular juvenile idiopathic arthritis (oligo JIA) is defined by limited joint involvement at disease onset. Some children achieve long-term remission while others continue to…
  • « Previous Page
  • 1
  • …
  • 17
  • 18
  • 19
  • 20
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology